359 related articles for article (PubMed ID: 11036336)
1. [Treatment of localized prostatic cancer--different alternatives. Patients with localized prostatic cancer must actively participate in the choice of therapy].
Adolfsson J
Lakartidningen; 2000 Sep; 97(36):3870-4. PubMed ID: 11036336
[TBL] [Abstract][Full Text] [Related]
2. The Prostate cancer Intervention Versus Observation Trial:VA/NCI/AHRQ Cooperative Studies Program #407 (PIVOT): design and baseline results of a randomized controlled trial comparing radical prostatectomy to watchful waiting for men with clinically localized prostate cancer.
Wilt TJ; Brawer MK; Barry MJ; Jones KM; Kwon Y; Gingrich JR; Aronson WJ; Nsouli I; Iyer P; Cartagena R; Snider G; Roehrborn C; Fox S
Contemp Clin Trials; 2009 Jan; 30(1):81-7. PubMed ID: 18783735
[TBL] [Abstract][Full Text] [Related]
3. Long-term outcome of patients with prostate cancer and pathologic seminal vesicle invasion (pT3b): effect of adjuvant radiotherapy.
Lee HM; Solan MJ; Lupinacci P; Gomella LG; Valicenti RK
Urology; 2004 Jul; 64(1):84-9. PubMed ID: 15245941
[TBL] [Abstract][Full Text] [Related]
4. Early outcomes of active surveillance for localized prostate cancer.
Hardie C; Parker C; Norman A; Eeles R; Horwich A; Huddart R; Dearnaley D
BJU Int; 2005 May; 95(7):956-60. PubMed ID: 15839912
[TBL] [Abstract][Full Text] [Related]
5. Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate-specific antigen testing: 15-year outcome.
Ward JF; Slezak JM; Blute ML; Bergstralh EJ; Zincke H
BJU Int; 2005 Apr; 95(6):751-6. PubMed ID: 15794776
[TBL] [Abstract][Full Text] [Related]
6. Decision analysis using individual patient preferences to determine optimal treatment for localized prostate cancer.
Sommers BD; Beard CJ; D'Amico AV; Dahl D; Kaplan I; Richie JP; Zeckhauser RJ
Cancer; 2007 Nov; 110(10):2210-7. PubMed ID: 17893907
[TBL] [Abstract][Full Text] [Related]
7. Decision analyses in consideration of treatment strategies for patients with biochemical failure after curative therapy on clinically localized prostate cancer in the prostate-specific antigen era.
Shimizu F; Igarashi A; Fukuda T; Kawachi Y; Minowada S; Ohashi Y; Fujime M
Jpn J Clin Oncol; 2007 Oct; 37(10):763-74. PubMed ID: 17956899
[TBL] [Abstract][Full Text] [Related]
8. Radical prostatectomy, radiotherapy or deferred treatment for localized prostate cancer?
Adolfsson J
Cancer Surv; 1995; 23():141-8. PubMed ID: 7621454
[TBL] [Abstract][Full Text] [Related]
9. Conservative management of prostate cancer in the prostate specific antigen era: the incidence and time course of subsequent therapy.
Zietman AL; Thakral H; Wilson L; Schellhammer P
J Urol; 2001 Nov; 166(5):1702-6. PubMed ID: 11586206
[TBL] [Abstract][Full Text] [Related]
10. Preoperative serum prostate specific antigen levels between 2 and 22 ng./ml. correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng./ml.
Stamey TA; Johnstone IM; McNeal JE; Lu AY; Yemoto CM
J Urol; 2002 Jan; 167(1):103-11. PubMed ID: 11743285
[TBL] [Abstract][Full Text] [Related]
11. Rising prostate specific antigen after radical prostatectomy: a case based review.
Nasr R; Goldenberg SL
Can J Urol; 2001 Aug; 8(4):1306-13. PubMed ID: 11564273
[TBL] [Abstract][Full Text] [Related]
12. Prostate cancer disease-free survival after radical retropubic prostatectomy in patients older than 70 years compared to younger cohorts.
Malaeb BS; Rashid HH; Lotan Y; Khoddami SM; Shariat SF; Sagalowsky AI; McConnell JD; Roehrborn CG; Koeneman KS
Urol Oncol; 2007; 25(4):291-7. PubMed ID: 17628294
[TBL] [Abstract][Full Text] [Related]
13. 13-year outcomes following treatment for clinically localized prostate cancer in a population based cohort.
Albertsen PC; Hanley JA; Penson DF; Barrows G; Fine J
J Urol; 2007 Mar; 177(3):932-6. PubMed ID: 17296379
[TBL] [Abstract][Full Text] [Related]
14. [Treatment strategy of localized prostate cancer].
Maeda O
Gan To Kagaku Ryoho; 2003 Jan; 30(1):26-31. PubMed ID: 12557701
[TBL] [Abstract][Full Text] [Related]
15. Controversies in prostate cancer radiotherapy: consensus development.
Lukka H; Warde P; Pickles T; Morton G; Brundage M; Souhami L;
Can J Urol; 2001 Aug; 8(4):1314-22. PubMed ID: 11564274
[TBL] [Abstract][Full Text] [Related]
16. Global update on defining and treating high-risk localized prostate cancer with leuprorelin: a USA perspective--identifying men at diagnosis who are at high risk of prostate cancer death after surgery or radiation therapy.
D'Amico A
BJU Int; 2007 Jan; 99 Suppl 1():13-6; discussion 17-8. PubMed ID: 17229162
[TBL] [Abstract][Full Text] [Related]
17. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
18. Digital rectal examination is no longer necessary in the routine follow-up of men with undetectable prostate specific antigen after radical prostatectomy: the implications for follow-up.
Chaplin BJ; Wildhagen MF; Schroder FH; Kirkels WJ; Bangma CH
Eur Urol; 2005 Dec; 48(6):906-10. PubMed ID: 16126322
[TBL] [Abstract][Full Text] [Related]
19. Prostate specific antigen recurrence after definitive therapy.
Freedland SJ; Moul JW
J Urol; 2007 Jun; 177(6):1985-91. PubMed ID: 17509277
[TBL] [Abstract][Full Text] [Related]
20. What PCPs and geriatricians need to know about robotic prostatectomy and organ-confined prostate cancer.
Carlucci JR; Nabizada-Pace F; Samadi DB
Geriatrics; 2009 Feb; 64(2):8-14. PubMed ID: 19256581
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]